Abstract Library

#4549 Alpha-Fetoprotein as a valuable biomarker in neuroendocrine tumours

Introduction: Neuroendocrine tumours (NETs) are a rare group of tumours that pose a significant diagnostic, therapeutic, and prognostic challenge. This complexity arises from the diversity and heterogeneity of these neoplasms, as well as from the limitations of commonly used biomarkers in clinical practice. Alpha-fetoprotein (AFP) is a fetal protein widely used primarily for congenital defects in prenatal diagnostics and in certain malignancies in adults.

Conference:

Presenting Author:

Authors: Musiałkiewicz J, Gut P, Komarnicki P, Maciejewski A, Ruchała M,

Keywords: alpha-fetoprotein, biomarker, neuroendocrine tumour,

#4528 Serum visfatin concentration in metastatic pancreatic and midgut NETs: An exploratory study

Introduction: Neuroendocrine tumours (NETs) are commonly diagnosed at advanced stages due to their diverse and often asymptomatic clinical presentation. Visfatin, an adipocytokine involved in regulating cellular energy homeostasis, inflammation, and tumorigenesis, has been investigated as a potential biomarker in several neoplasms. However, its role in NETs remains unexplored.

Conference:

Presenting Author:

Authors: Komarnicki P, Maciejewski A, Musiałkiewicz J, Mastorakos G, Gut P,

Keywords: visfatin, biomarker, nicotinamide phosphoribosyltransferase, NAMPT, PBEF, eNAMPT,

#4045 Radio-guided surgery with a new generation β-probe for radiolabelled somatostatin analogue, in patients with small intestinal neuroendocrine tumors – A Phase II surgical trial

Introduction: Radio-guided surgery (RGS) proved to be promising in neuroendocrine tumors (NETs). Previous studies showed high sensitivity but low specificity using gamma probes to detect radiation emitted by radio-labelled somatostatin analogues.

Conference:

Presenting Author: Danieli M

Authors: Bertani E, Fumagalli Romario U, Collamati F, Mattana F, Fazio N,

Keywords: Radio-guided surgery, small-intestinal neuroendocrine tumor, small-intestinal resection, beta-probe, radiolabelled somatostatine analogues, surgery, lymphadenectomy,

#3977 Serum b-HCG as a biomarker in neuroendocrine tumors: A reconsideration of single-analyte approach

Introduction: Despite recent advances, neuroendocrine tumors (NETs) remain a challenging topic due to their diverse characteristics and the lack of suitable biomarkers. The shift to an omics-based approach and the utilization of statistical algorithms present an improvement over the traditional single-analyte strategy, albeit with its own drawbacks.

Conference:

Presenting Author: Komarnicki P

Authors: Komarnicki P, Gut P, Musiałkiewicz J, Maciejewski A, Cieślewicz M,

Keywords: pancreatic neoplasms, neuroendocrine tumor, biomarker, chorionic gonadotropin, hcg-beta,

#2880 177-Lu-DOTATATE in 200 Patients with Neuroendocrine Tumors: Real-World Data from the SEPTRALU Registry

Introduction: Patients with neuroendocrine tumors have few treatment options after progression to first-line somatostatin analogues.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Carmona Bayonas A

Authors: Carmona-Bayonas A, Mitjavila Casanovas M, Belló P, Percovich J, Prieto A,

Keywords: PRRT, 177Lu-DOTATATE, radionuclide,